tirzepatide chronic kidney disease trial A comparison of the effects of and dulaglutide on major events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT Tirzepatide improves kidney outcomes in

Tirzepatide is given as an injection

The cardinal rule of titration: the timeline is a floor, not a ceiling

Youre Still Taking a Starter Dose One of the most common reasons people arent losing weight on tirzepatide is that theyre still on the introductory dose

A low carb diet supports: Fat loss Blood sugar control Muscle preservation Improved satiety Reduced cravings Long-term weight maintenance By focusing on protein, nutrient density, hydration, and supportive low carb products, GLP-1 users can transform short-term weight loss into lasting health

In May 2026, BrightGene Bio-Medicals Phase III clinical trial evaluating its dual-agonist injection, BGM0504, successfully met its primary endpoint and all key secondary endpoints for overweight and obesity management